Melanoma

Oncology 10 original drugs

Novel Drugs

Reformulations

Drug Targets

Oncology indication. Melanoma has 10 FDA-approved novel treatments, led by Roche, with 521 active industry clinical trials across 19 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Melanoma Market Leaders

Companies with the most FDA-approved novel Melanoma drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

HBI-8000 in combination with nivolumab

HUYABIO International, LLC.

Estimated · aging NCT04674683

Q1 2027

IDE196

IDEAYA Biosciences

Estimated · fresh NCT05987332

Q1 2027

BCD-217

Biocad

Estimated · aging NCT05751928

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Melanoma Treatments by Mechanism

Top 12 mechanisms across 89 industry trials with a known mechanism of action.

See full pipeline →

Programmed Death Receptor-1 Blocking Antibody

38 trials 4 active 7 sponsors

ALK/ROS1/NTRK1/TRKB/TRKC

1 trials 1 active 1 sponsor

CTLA-4-directed Blocking Antibody

16 trials 3 sponsors

Kinase Inhibitor

15 trials 4 sponsors

GM-CSF

10 trials 2 sponsors

Programmed Death Ligand-1 Blocker

2 trials 2 sponsors

Azole Antifungal

2 trials 1 sponsor

Lymphocyte Growth Factor

1 trials 1 sponsor

Photoactivated Radical Generator

1 trials 1 sponsor

CD30-directed Immunoconjugate

1 trials 1 sponsor

Alkylating Drug

1 trials 1 sponsor

CD25-directed Cytotoxin

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Melanoma Clinical Pipeline by Phase

731 industry-sponsored trials across 322 sponsors

View full landscape →

Showing 9 of 9 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Novartis	dabrafenib	—	RECRUITING	2032-12-28	NCT03340506
Bristol-Myers Squibb	Nivolumab + Relatlimab	—	NOT YET RECRUITING	2029-05-26	NCT07459543
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2024-08-21	NCT03715205
RECORDATI GROUP	Pasireotide	—	COMPLETED	2023-07-25	NCT01794793
Novartis	Nilotinib	—	COMPLETED	2023-07-07	NCT01735955
Roche	Zelboraf	Kinase Inhibitor [EPC]	COMPLETED	2019-05-22	NCT01898585
Novartis	Aldesleukin	Lymphocyte Growth Factor [EPC]	COMPLETED	2010-03-28	NCT00414765
Clinigen, Inc.	High Dose Interleukin-2	—	TERMINATED	2015-07	NCT01856023
Clinigen, Inc.	vemurafenib + HD IL-2	—	TERMINATED	2014-11	NCT01683188

Showing 88 of 88 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Regeneron	fianlimab	—	RECRUITING	2027-03-22	NCT06246916
mAbxience Research S.L.	MB11 (Proposed Nivolumab Biosimilar)	—	RECRUITING	2027-04	NCT07221734
Shanghai Kechow Pharma, Inc.	tunlametinib	—	RECRUITING	2027-09-22	NCT06008106
Immunocore Ltd	Brenetafusp	—	RECRUITING	2027-10-16	NCT06112314
Aura Biosciences	Bel-sar	—	RECRUITING	2027-11-15	NCT06007690
Philogen S.p.A.	Daromun	—	RECRUITING	2027-12	NCT03567889
Immatics US, Inc.	IMA203	—	RECRUITING	2028-01	NCT06743126
Immunocore Ltd	Tebentafusp	—	RECRUITING	2028-03	NCT05549297
Iovance Biotherapeutics, Inc.	Lifileucel plus Pembrolizumab	—	RECRUITING	2028-03-01	NCT05727904
Replimune, Inc.	Vusolimogene Oderparepvec	—	RECRUITING	2029-01-01	NCT06264180
Linnaeus Therapeutics, Inc.	LNS8801	—	RECRUITING	2029-02	NCT06624644
Replimune, Inc.	RP2	—	RECRUITING	2030-01	NCT06581406
IDEAYA Biosciences	Darovasertib	—	RECRUITING	2030-10	NCT07015190
Eikon Therapeutics	EIK1001	—	RECRUITING	2035-12	NCT06697301
Binhui Biopharmaceutical Co., Ltd.	OH2	—	RECRUITING	2026-03	NCT05868707
Biocad	BCD-217	—	ACTIVE NOT RECRUITING	2027-01	NCT05751928
IDEAYA Biosciences	IDE196	—	ACTIVE NOT RECRUITING	2027-01-15	NCT05987332
Pierre Fabre Medicament	Encorafenib and Binimetinib	—	ACTIVE NOT RECRUITING	2027-03-31	NCT05270044
Amgen	ABP 206	—	ACTIVE NOT RECRUITING	2028-01-25	NCT06054555
Erasca, Inc.	Naporafenib	—	ACTIVE NOT RECRUITING	2028-04	NCT06346067
Regeneron	Fianlimab	—	ACTIVE NOT RECRUITING	2028-05-16	NCT05608291
Merck	Intismeran autogene	—	ACTIVE NOT RECRUITING	2029-10-26	NCT05933577
HUYABIO International, LLC.	HBI-8000 in combination with nivolumab	—	ACTIVE NOT RECRUITING	2026-07	NCT04674683
Regeneron	Fianlimab	—	ACTIVE NOT RECRUITING	2026-03-12	NCT05352672
Pfizer	Encorafenib	—	ACTIVE NOT RECRUITING	2026-01-12	NCT04657991
Biocad	BCD-263	—	ACTIVE NOT RECRUITING	2025-12	NCT06640530
Bristol-Myers Squibb	Nivolumab + Relatlimab	—	ACTIVE NOT RECRUITING	2025-08-04	NCT05625399
IO Biotech	IO102-IO103	—	ACTIVE NOT RECRUITING	2025-05-30	NCT05155254
Philogen S.p.A.	L19IL2 + L19TNF	—	ACTIVE NOT RECRUITING	2024-10	NCT02938299
Biocad	BCD-217	—	ACTIVE NOT RECRUITING	2024-06-20	NCT05732805
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2022-06-28	NCT04099251
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2021-06-21	NCT03553836
Bristol-Myers Squibb	Relatlimab	—	ACTIVE NOT RECRUITING	2021-01-25	NCT03470922
Merck	pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2018-01-08	NCT02362594
Amgen	ABP 206	—	COMPLETED	2025-03-26	NCT05907122
Merck	Pembrolizumab/Vibostolimab	—	COMPLETED	2024-03-06	NCT05665595
Bristol-Myers Squibb	Nivolumab/rHuPH20	—	COMPLETED	2024-02-08	NCT05297565
Delcath Systems Inc.	—	—	COMPLETED	2023-05-18	NCT02678572
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2023-01-18	NCT03820986
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2023-01-18	NCT04889118
Bristol-Myers Squibb	NKTR-214	—	COMPLETED	2021-11-19	NCT03635983
Novartis	Dabrafenib	—	COMPLETED	2020-10-05	NCT03551626
Bristol-Myers Squibb	BMS-986205	—	COMPLETED	2020-07-02	NCT03329846
Bristol-Myers Squibb	nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2020-06-12	NCT03068455
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2020-02-10	NCT02599402
Roche	Atezolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2019-10-11	NCT02908672
Bristol-Myers Squibb	Ipilimumab	CTLA-4-directed Blocking Antibody [EPC]	COMPLETED	2019-04-19	NCT02545075
Bristol-Myers Squibb	Ipilimumab	CTLA-4-directed Blocking Antibody [EPC]	COMPLETED	2018-11-26	NCT02388906
Incyte Corporation	pembrolizumab + epacadostat	—	COMPLETED	2018-01-08	NCT02752074
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2017-10-23	NCT02905266
Novartis	Dabrafenib	—	COMPLETED	2017-06-30	NCT01682083
Roche	Vemurafenib	Kinase Inhibitor [EPC]	COMPLETED	2017-06-23	NCT01667419
Bristol-Myers Squibb	Nivolumab 3 mg/kg IV	—	COMPLETED	2017-04-20	NCT02714218
Pfizer	LGX818	—	COMPLETED	2016-11-09	NCT01909453
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2016-08-01	NCT01844505
Roche	Vemurafenib	Kinase Inhibitor [EPC]	COMPLETED	2016-02-24	NCT01307397
Bristol-Myers Squibb	BMS-936558	—	COMPLETED	2016-02-16	NCT01721746
Bristol-Myers Squibb	Ipilimumab	CTLA-4-directed Blocking Antibody [EPC]	COMPLETED	2016-02-06	NCT01515189
Pfizer	MEK162	—	COMPLETED	2015-12-01	NCT01763164
AstraZeneca	75mg selumetinib	—	COMPLETED	2015-05	NCT01974752
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2015-03-03	NCT01866319
BioVex Limited	Talimogene Laherparepvec	GM-CSF	COMPLETED	2014-09	NCT01368276
Bristol-Myers Squibb	BMS-936558 (Nivolumab)	—	COMPLETED	2014-06-24	NCT01721772
Roche	Vemurafenib	Kinase Inhibitor [EPC]	COMPLETED	2014-05-09	NCT01689519
Novartis	Dabrafenib	—	COMPLETED	2014-04-17	NCT01597908
Novartis	Dabrafenib	—	COMPLETED	2013-08-26	NCT01584648
Bristol-Myers Squibb	ipilimumab	CTLA-4-directed Blocking Antibody [EPC]	COMPLETED	2013-07-26	NCT00636168
BioVex Limited	Talimogene laherparepvec	GM-CSF	COMPLETED	2013-02	NCT00769704
Bristol-Myers Squibb	ABI-007	—	COMPLETED	2012-06-01	NCT00864253
GSK	GSK1120212	—	COMPLETED	2011-10-26	NCT01245062
Navidea Biopharmaceuticals	Lymphoseek	—	COMPLETED	2011-04	NCT01106040
Roche	Vemurafenib	Kinase Inhibitor [EPC]	COMPLETED	2010-12	NCT01006980
Navidea Biopharmaceuticals	Lymphoseek	—	COMPLETED	2009-06	NCT00671918
Novartis	JPB898 (Induction and Maintenance)	—	TERMINATED	2026-01-23	NCT06587451
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	TERMINATED	2024-12-16	NCT05002569
Regeneron	CMP-001	—	TERMINATED	2024-07-22	NCT04695977
Innovent Biologics (Suzhou) Co. Ltd.	IBI310+IBI308	—	TERMINATED	2023-02-28	NCT04277663
Nektar Therapeutics	Bempegaldesleukin	—	TERMINATED	2022-09-22	NCT04410445
Idera Pharmaceuticals, Inc.	Ipilimumab	CTLA-4-directed Blocking Antibody [EPC]	TERMINATED	2021-06-01	NCT03445533
Polynoma LLC	POL-103A	—	TERMINATED	2021-04-29	NCT01546571
Amgen	Talimogene Laherparepvec	GM-CSF	TERMINATED	2021-03-11	NCT02263508
Novartis	Spartalizumab	—	TERMINATED	2020-08-11	NCT02967692
AB Science	Masitinib	—	TERMINATED	2019-08	NCT01280565
Roche	Cobimetinib	—	TERMINATED	2019-04-15	NCT03273153
Provectus Biopharmaceuticals, Inc.	PV-10 (10% rose bengal disodium)	—	TERMINATED	2019-04	NCT02288897
GSK	GSK 2132231A	—	TERMINATED	2016-01-27	NCT00796445
Lisata Therapeutics, Inc.	Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)	—	TERMINATED	2016-01	NCT01875653
Eli Lilly	Tasisulam-sodium	—	TERMINATED	2011-03	NCT01006252

Showing 100 of 331 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
OncoResponse, Inc.	OR502	—	RECRUITING	2026-08-01	NCT06090266
ImmVira Pharma Co. Ltd	T3011	—	RECRUITING	2026-09-22	NCT04370587
Shanghai Pharmaceuticals Holding Co., Ltd	T3011	—	RECRUITING	2026-09-30	NCT06214156
Shanghai JMT-Bio Inc.	JMT108	—	RECRUITING	2026-11-30	NCT07280832
Georgiamune Inc	GIM-531	—	RECRUITING	2026-12	NCT06425926
Beijing Scitech-Mq Pharmaceuticals Limited	ST-1898 tablets	—	RECRUITING	2026-12	NCT06359860
GV20 Therapeutics	GV20-0251	—	RECRUITING	2026-12-15	NCT05669430
Psyence Australia Pty Ltd	Psilocybin therapy	—	RECRUITING	2026-12-30	NCT07072728
BioInvent International AB	BI-1808	—	RECRUITING	2026-12-31	NCT04752826
IDEAYA Biosciences	IDE196	—	RECRUITING	2027-01-29	NCT03947385
Neonc Technologies, Inc.	NEO212 Oral Capsule	—	RECRUITING	2027-02-28	NCT06047379
Beijing Biotech	EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells	—	RECRUITING	2027-06-14	NCT07627698
Hummingbird Bioscience	ENV-501	—	RECRUITING	2027-07	NCT06956690
Krystal Biotech, Inc.	KB707	—	RECRUITING	2027-07	NCT05970497
GV20 Therapeutics	GV20-0251	—	RECRUITING	2027-07-16	NCT07070518
Iovance Biotherapeutics, Inc.	IOV-4001	—	RECRUITING	2027-09	NCT05361174
Daiichi Sankyo	HER3-DXd	—	RECRUITING	2027-09-01	NCT06172478
Nanjing Leads Biolabs Co.,Ltd	LBL-024 for Injection	—	RECRUITING	2027-10-30	NCT07099430
Toray Industries, Inc	TRK-950	—	RECRUITING	2027-12	NCT05423262
Suzhou BlueHorse Therapeutics Co., Ltd.	LM103 TILs Injection	—	RECRUITING	2027-12-31	NCT07310784
Hangzhou Hanx Biopharmaceuticals, Ltd.	HX009+IN10018	—	RECRUITING	2027-12-31	NCT06708663
7 Hills Pharma, LLC	Alintegimod	—	RECRUITING	2027-12-31	NCT06362369
Perspective Therapeutics	[203Pb]VMT01	—	RECRUITING	2027-12-31	NCT05655312
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	RECRUITING	2028-02-02	NCT02332668
Aminex Therapeutics, Inc.	AMXT 1501 Dicaprate	—	RECRUITING	2028-02-28	NCT07287917
Novelwise Pharmaceutical Corporation	NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.	—	RECRUITING	2028-03-28	NCT07136181
Onchilles Pharma Inc	N17350	—	RECRUITING	2028-07	NCT07339176
Philogen S.p.A.	L19IL2	—	RECRUITING	2028-07	NCT06284590
Merck	Intismeran autogene	—	RECRUITING	2028-07-22	NCT06961006
Beijing Tide Pharmaceutical Co., Ltd	TCC1727 tablet 90mg	—	RECRUITING	2028-09-30	NCT07371663
Obsidian Therapeutics, Inc.	OBX-115	—	RECRUITING	2029-06-30	NCT06060613
Hanmi Pharmaceutical Company Limited	Belvarafenib	—	RECRUITING	2029-09	NCT07449754
AstraZeneca	AZD6750	—	RECRUITING	2029-10-02	NCT07115043
Regeneron	REGN10597	—	RECRUITING	2030-02-03	NCT06413680
Diakonos Oncology Corporation	DOC1021	—	RECRUITING	2031-01	NCT07288112
Bristol-Myers Squibb	BMS-986340	—	RECRUITING	2031-08-31	NCT04895709
Iovance Biotherapeutics, Inc.	IOV-3001	—	RECRUITING	2032-06	NCT06940739
Shanghai Juncell Therapeutics	GC101 TIL	—	RECRUITING	2026-07-10	NCT06703398
CJ Bioscience, Inc.	CJRB-101	—	RECRUITING	2026-07	NCT05877430
Medicenna Therapeutics, Inc.	MDNA11	—	RECRUITING	2026-06-30	NCT05086692
Aulos Bioscience, Inc.	AU-007	—	RECRUITING	2026-06-12	NCT05267626
Multitude Therapeutics Inc.	AMT-253 for injection	—	RECRUITING	2026-04-30	NCT06209580
Innovent Biologics (Suzhou) Co. Ltd.	IBI363	—	RECRUITING	2026-03-31	NCT06797297
Binhui Biopharmaceutical Co., Ltd.	OH2 injection	—	RECRUITING	2026-03-13	NCT04386967
Innovent Biologics (Suzhou) Co. Ltd.	IBI363	—	RECRUITING	2026-03-01	NCT06281678
Innolake Biopharm	ILB-2109	—	RECRUITING	2026-01-25	NCT05955105
Rapa Therapeutics LLC	RAPA-201 Rapamycin Resistant T Cells	—	RECRUITING	2026-01-01	NCT05144698
Binhui Biopharmaceutical Co., Ltd.	OH2 injection	—	RECRUITING	2025-11-30	NCT04616443
GI Innovation, Inc.	GI-102 subcutaneous (SC)	—	RECRUITING	2025-11-12	NCT05824975
Simcha IL-18, Inc.	ST-067	—	RECRUITING	2025-06-30	NCT04787042
Innovent Biologics (Suzhou) Co. Ltd.	IBI363	—	RECRUITING	2025-06-06	NCT06081920
Vyriad, Inc.	VV1	—	RECRUITING	2025-06	NCT04291105
GeneMedicine Co., Ltd.	GM103 (Part A)	—	RECRUITING	2025-05-30	NCT06265025
Zhuhai Yufan Biotechnologies Co., Ltd	PRJ1-3024	—	RECRUITING	2025-04-30	NCT06727630
IO Biotech	IO102-IO103	—	RECRUITING	2025-04-30	NCT05280314
DermBiont, Inc.	SM-020 1% Gel	—	RECRUITING	2024-11	NCT06409195
GSK	Cobolimab	—	ACTIVE NOT RECRUITING	2026-10-13	NCT06521567
Inhibrx Biosciences, Inc	INBRX-106 - Hexavalent OX40 agonist antibody	—	ACTIVE NOT RECRUITING	2026-10-30	NCT04198766
Regeneron	cemiplimab	—	ACTIVE NOT RECRUITING	2026-11-02	NCT06190951
Sapience Therapeutics	ST101	—	ACTIVE NOT RECRUITING	2026-12	NCT04478279
Scancell Ltd	SCIB1 or iSCIB1+ DNA vaccine	—	ACTIVE NOT RECRUITING	2027-01-31	NCT04079166
Novartis	LXH254	—	ACTIVE NOT RECRUITING	2027-02-02	NCT04417621
IDEAYA Biosciences	Darovasertib	—	ACTIVE NOT RECRUITING	2027-04-30	NCT05907954
Sensei Biotherapeutics, Inc.	SNS-101 (anti-VISTA)	—	ACTIVE NOT RECRUITING	2027-06	NCT05864144
Roche	RO7247669	—	ACTIVE NOT RECRUITING	2027-06-30	NCT04140500
Roche	Entrectinib	ALK/ROS1/NTRK1/TRKB/TRKC	ACTIVE NOT RECRUITING	2027-06-30	NCT02568267
Ascendis Pharma Oncology Division A/S	TransCon IL-2 β/γ	—	ACTIVE NOT RECRUITING	2027-08	NCT05081609
Novartis	DYP688	—	ACTIVE NOT RECRUITING	2027-10-01	NCT05415072
iOnctura	roginolisib	—	ACTIVE NOT RECRUITING	2027-12	NCT06717126
Agenus Inc.	Botensilimab	—	ACTIVE NOT RECRUITING	2028-02	NCT05529316
Ipsen	IPN01194	—	ACTIVE NOT RECRUITING	2028-03-20	NCT06305247
Replimune, Inc.	RP1	—	ACTIVE NOT RECRUITING	2028-06	NCT03767348
ImmunityBio, Inc.	N-803 + Pembrolizumab	—	ACTIVE NOT RECRUITING	2029-08-31	NCT03228667
ModernaTX, Inc.	mRNA-4157	—	ACTIVE NOT RECRUITING	2032-11-30	NCT03897881
Iovance Biotherapeutics, Inc.	Lifileucel	—	ACTIVE NOT RECRUITING	2032-12	NCT07288203
OncoC4, Inc.	ONC-392	—	ACTIVE NOT RECRUITING	2026-06-30	NCT04140526
Immuneering Corporation	IMM-1-104 Monotherapy (Treatment Group A)	—	ACTIVE NOT RECRUITING	2026-06	NCT05585320
ENB Therapeutics, Inc	ENB003	—	ACTIVE NOT RECRUITING	2026-01-01	NCT04205227
Genmab	GEN1042	—	ACTIVE NOT RECRUITING	2025-12-30	NCT04083599
BioInvent International AB	pembrolizumab (KEYTRUDA®)	—	ACTIVE NOT RECRUITING	2025-12-30	NCT06784648
Ascentage Pharma Group Inc.	Phase 1b: APG-115+pembrolizumab	—	ACTIVE NOT RECRUITING	2025-12-30	NCT03611868
Salubris Biotherapeutics Inc	JK08	—	ACTIVE NOT RECRUITING	2025-10-17	NCT05620134
Evaxion Biotech A/S	EVX-01	—	ACTIVE NOT RECRUITING	2025-09-30	NCT05309421
ImaginAb, Inc.	zirconium Zr 89 crefmirlimab berdoxam	—	ACTIVE NOT RECRUITING	2025-07	NCT05013099
BeiGene	BGB-A445	—	ACTIVE NOT RECRUITING	2025-05-27	NCT05661955
Bristol-Myers Squibb	relatlimab+nivolumab	—	ACTIVE NOT RECRUITING	2025-04-10	NCT06101134
Merck	Pembrolizumab (+) Berahyaluronidase alfa	—	ACTIVE NOT RECRUITING	2025-04-09	NCT06099782
BioAtla, Inc.	BA3071	—	ACTIVE NOT RECRUITING	2025-03-19	NCT05180799
NGM Biopharmaceuticals, Inc	NGM707	—	ACTIVE NOT RECRUITING	2025-02	NCT04913337
iTeos Belgium SA	EOS-448	—	ACTIVE NOT RECRUITING	2024-07	NCT05060432
AstraZeneca	Ceralasertib	—	ACTIVE NOT RECRUITING	2024-04-12	NCT05061134
AstraZeneca	Trastuzumab deruxtecan	—	ACTIVE NOT RECRUITING	2023-01-25	NCT04639219
Second Life Therapeutics	SL-28	—	NOT YET RECRUITING	2027-01-01	NCT07341737
Oncodesign Precision Medicine	OPM-101	—	NOT YET RECRUITING	2027-09	NCT07040436
Primmune Therapeutics, Inc.	PRTX007	—	NOT YET RECRUITING	2027-12	NCT07565285
Xynomic Pharmaceuticals, Inc.	XP-102	—	NOT YET RECRUITING	2027-12-30	NCT05275374
Qingdao Sino-Cell Biomedicine Co., Ltd.	Lymphodepletion Conditioning	—	NOT YET RECRUITING	2027-12-31	NCT07406724
Therakos LLC	methoxsalen	Photoactivated Radical Generator [EPC]	NOT YET RECRUITING	2028-12	NCT07619898
Rapa Therapeutics LLC	RAPA-201 Rapamycin Resistant T Cells	—	NOT YET RECRUITING	2029-03-01	NCT06708455
VM Discovery, Inc.	VMD-102	—	NOT YET RECRUITING	2031-05	NCT07636785

Showing 100 of 303 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Nurix Therapeutics, Inc.	NX-1607	—	RECRUITING	2026-08-31	NCT05107674
Adze Biotechnology Australia Pty Ltd	Adze1.C	—	RECRUITING	2026-11-30	NCT07086105
Compass Therapeutics	CTX-8371	—	RECRUITING	2026-12	NCT06150664
ViroMissile, Inc.	IDOV-Immune (oncolytic vaccinia virus)	—	RECRUITING	2027-01-31	NCT06910657
Memgen, Inc.	MEM-288 Intratumoral Injection	—	RECRUITING	2027-02	NCT05076760
MonTa Biosciences ApS	MBS8(1V270)	—	RECRUITING	2027-03	NCT04855435
Guangzhou FineImmune Biotechnology Co., LTD.	Super1 TCR-T	—	RECRUITING	2027-04-25	NCT06942143
Valo Therapeutics Oy	PeptiCRAd-1	—	RECRUITING	2027-04-30	NCT05492682
Shanghai Henlius Biotech	HLX17	—	RECRUITING	2027-04-30	NCT07160335
Rise Therapeutics LLC	R-5780	—	RECRUITING	2027-04-30	NCT06398418
Chiome Bioscience Inc.	CBA-1205 Part 1	—	RECRUITING	2027-06-30	NCT06636435
Pfizer	PF-07799544	—	RECRUITING	2027-08-02	NCT05538130
Novelty Nobility, Inc.	NN3201	—	RECRUITING	2027-08-30	NCT06805825
KaliVir Immunotherapeutics	VET3-TGI	—	RECRUITING	2027-09-30	NCT06444815
LG Chem	Phase 1a: LB-LR1109	—	RECRUITING	2027-11	NCT06332755
Relay Therapeutics, Inc.	RLY-8161	—	RECRUITING	2027-12-30	NCT07584226
Alpha-9 Oncology USA Inc.	[225Ac]Ac-A9-3408	—	RECRUITING	2028-01	NCT07076550
Pfizer	PF-07799933	—	RECRUITING	2028-04-23	NCT05355701
MacroGenics	MGC026 Dose Escalation	—	RECRUITING	2028-05	NCT06242470
Pfizer	PF-08046033	—	RECRUITING	2028-07-14	NCT07519655
Roche	Enzelkitug	—	RECRUITING	2028-07-31	NCT05581004
Nested Therapeutics, Inc	NST-628	—	RECRUITING	2028-11	NCT06326411
Kupando GmbH	KUP-101A	—	RECRUITING	2028-12	NCT07600476
Immatics US, Inc.	IMA203	—	RECRUITING	2029-08	NCT06946225
Boehringer Ingelheim	BI 3810944	—	RECRUITING	2029-10-05	NCT07224425
Hangzhou DAC Biotechnology Co., Ltd.	DXC014	—	RECRUITING	2030-10-20	NCT07177937
OncoNano Medicine, Inc.	ONM-501	—	RECRUITING	2026-04-30	NCT06022029
Shandong Boan Biotechnology Co., Ltd	BA1302	—	RECRUITING	2025-12-31	NCT06596915
BioEclipse Therapeutics	CRX100 suspension for infusion	—	RECRUITING	2025-08	NCT04282044
Suzhou BlueHorse Therapeutics Co., Ltd.	Autologous tumor infiltrating lymphocytes (TILs)	—	RECRUITING	2024-05-30	NCT05366478
Aivita Biomedical, Inc.	AV-MEL-1	—	RECRUITING	2024-05	NCT03743298
OncoC4, Inc.	AI-061	—	ACTIVE NOT RECRUITING	2026-07-31	NCT05858736
Syntrix Biosystems, Inc.	SX-682	—	ACTIVE NOT RECRUITING	2026-08	NCT03161431
Asher Biotherapeutics, Inc.	etakafusp alfa (AB248)	—	ACTIVE NOT RECRUITING	2026-08	NCT05653882
Boehringer Ingelheim	BI 765063	—	ACTIVE NOT RECRUITING	2026-09-16	NCT05068102
Novartis	DKY709	—	ACTIVE NOT RECRUITING	2026-10-30	NCT03891953
TILT Biotherapeutics Ltd.	TILT-123	—	ACTIVE NOT RECRUITING	2026-11	NCT06961786
HiFiBiO Therapeutics	HFB200301	—	ACTIVE NOT RECRUITING	2026-12	NCT05238883
HiFiBiO Therapeutics	HFB200603	—	ACTIVE NOT RECRUITING	2026-12	NCT05789069
TILT Biotherapeutics Ltd.	TILT-123	—	ACTIVE NOT RECRUITING	2026-12	NCT05222932
USWM CT, LLC	—	—	ACTIVE NOT RECRUITING	2026-12-23	NCT04044859
TScan Therapeutics, Inc.	TSC-204-A0201	—	ACTIVE NOT RECRUITING	2026-12-30	NCT05973487
AgonOx, Inc.	DP CD8 TIL	—	ACTIVE NOT RECRUITING	2026-12-31	NCT05902520
NeoTX Therapeutics Ltd.	—	—	ACTIVE NOT RECRUITING	2027-03-01	NCT03983954
Modulation Therapeutics, Inc.	4.7 microCi 225Ac-MTI-201	—	ACTIVE NOT RECRUITING	2027-03-31	NCT05496686
Nanobiotix	NBTXR3	—	ACTIVE NOT RECRUITING	2027-04-30	NCT03589339
Roche	Belvarafenib	—	ACTIVE NOT RECRUITING	2027-06-30	NCT04835805
Novartis	KFA115	—	ACTIVE NOT RECRUITING	2027-09-01	NCT05544929
Pierre Fabre Medicament	KIN-2787	—	ACTIVE NOT RECRUITING	2028-11-30	NCT04913285
Iovance Biotherapeutics, Inc.	LN-145/LN-144	—	ACTIVE NOT RECRUITING	2026-07	NCT06566092
Formycon AG	FYB206	—	ACTIVE NOT RECRUITING	2026-06-30	NCT06551064
Seagen, a wholly owned subsidiary of Pfizer	PF-08046049	—	ACTIVE NOT RECRUITING	2026-06-06	NCT05571839
Novartis	GME751	—	ACTIVE NOT RECRUITING	2026-06	NCT06153238
Toray Industries, Inc	TRK-950	—	ACTIVE NOT RECRUITING	2026-06	NCT03872947
Phio Pharmaceuticals Inc.	PH-762	—	ACTIVE NOT RECRUITING	2025-12-29	NCT06014086
Microbiotica Ltd	MB097	—	ACTIVE NOT RECRUITING	2025-12	NCT06540391
Theratechnologies	TH1902	—	ACTIVE NOT RECRUITING	2025-12	NCT04706962
NGM Biopharmaceuticals, Inc	NGM831	—	ACTIVE NOT RECRUITING	2025-07	NCT05215574
RemeGen Co., Ltd.	RC198 Injection	—	ACTIVE NOT RECRUITING	2024-09-30	NCT05867303
Biomica Ltd.	BMC128	—	ACTIVE NOT RECRUITING	2024-05	NCT05354102
Biocad	BCD-263	—	ACTIVE NOT RECRUITING	2024-01-31	NCT06112808
iOnctura	IOA-244	—	ACTIVE NOT RECRUITING	2023-12-13	NCT04328844
USWM CT, LLC	—	—	ACTIVE NOT RECRUITING	2022-12-27	NCT03132922
Checkpoint Therapeutics, Inc.	CK-301 (cosibelimab)	—	ACTIVE NOT RECRUITING	2021-11-18	NCT03212404
Biotroy Therapeutics	BT02	—	NOT YET RECRUITING	2027-05	NCT07107178
AccSalus Biosciences, Inc.	ACC-1898	—	NOT YET RECRUITING	2027-06	NCT07252661
Shanghai Henlius Biotech	HLX18	—	NOT YET RECRUITING	2027-08-12	NCT07518043
Biocon Biologics UK PLC	Bmab1700	—	NOT YET RECRUITING	2027-08-16	NCT07476326
Alvotech Swiss AG	AVT32-DRL_PB	—	NOT YET RECRUITING	2027-10	NCT07475572
Biocon Biologics UK PLC	Bmab1800	—	NOT YET RECRUITING	2027-12-15	NCT07581509
C4 Therapeutics, Inc.	CFT1946	—	COMPLETED	2025-11-05	NCT05668585
Arcus Biosciences, Inc.	AB308	—	COMPLETED	2025-08-25	NCT04772989
Roche	Autogene cevumeran	—	COMPLETED	2025-07-01	NCT03289962
MacroGenics	vobramitamab duocarmazine	—	COMPLETED	2025-06-24	NCT05293496
Compass Therapeutics	CTX-471	—	COMPLETED	2025-05-21	NCT03881488
Xencor, Inc.	XmAb®808	—	COMPLETED	2025-05-20	NCT05585034
NantBioScience, Inc.	YE-NEO-001	—	COMPLETED	2025-03-18	NCT03552718
InxMed (Shanghai) Co., Ltd.	IN10018	—	COMPLETED	2024-12-20	NCT04109456
Bio-Thera Solutions	BAT4706	—	COMPLETED	2024-11-05	NCT05148325
AstraZeneca	AZD8701	—	COMPLETED	2024-10-07	NCT04504669
MacroGenics	Lorigerlimab	—	COMPLETED	2024-08-29	NCT03761017
Nanjing Leads Biolabs Co.,Ltd	LBL-007	—	COMPLETED	2024-08-19	NCT04640545
invoX Pharma Limited	SB 11285	—	COMPLETED	2024-07-16	NCT04096638
Roche	Lomvastomig	—	COMPLETED	2024-07-09	NCT03708328
Tvardi Therapeutics, Incorporated	TTI-101	—	COMPLETED	2024-06-24	NCT03195699
Gene Surgery LLC	Stimotimagene copolymerplasmid	—	COMPLETED	2024-04-11	NCT05578820
Xencor, Inc.	XmAb®23104	—	COMPLETED	2024-02-15	NCT03752398
TILT Biotherapeutics Ltd.	TILT-123	—	COMPLETED	2023-12-12	NCT04217473
Merck	Pembrolizumab Dose C	—	COMPLETED	2023-12-04	NCT03665597
TuHURA Biosciences, Inc.	IFx-Hu2.0	—	COMPLETED	2023-10-19	NCT04160065
Cantargia AB	CAN04	—	COMPLETED	2023-06-28	NCT04452214
BioNTech SE	Lipo-MERIT	—	COMPLETED	2023-06-20	NCT02410733
Shattuck Labs, Inc.	SL-279252	—	COMPLETED	2023-05-04	NCT03894618
Xencor, Inc.	XmAb®22841	—	COMPLETED	2023-02-16	NCT03849469
Prelude Therapeutics	PRT1419	—	COMPLETED	2023-02-06	NCT04837677
Pierre Fabre Medicament	Binimetinib 15 MG	—	COMPLETED	2022-12-22	NCT05810740
Regeneron	CMP-001	—	COMPLETED	2022-12-06	NCT02680184
Fate Therapeutics	FT500	—	COMPLETED	2022-11-15	NCT03841110
Ultimovacs ASA	UV1	—	COMPLETED	2022-10-01	NCT03538314
BerGenBio ASA	Bemcentinib	—	COMPLETED	2022-09-23	NCT06469138

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Melanoma

EGFR- (8) ALK- (7) PD-1 (7) BRAF (6) PD-L1 ≥1% (4) dMMR (4)

Novel Melanoma Drugs by Company (New molecular entities)

5 companies have an FDA-approved novel drug for Melanoma.

Roche 3 drugs

Bristol-Myers Squibb 3 drugs

Merck 2 drugs

Novartis 1 drug

CHIRON 1 drug

Reformulations (4 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.